Breathtec Biomedical (BTH: CNX) to Investigate Zika Virus Airborne Disease Detection

Spotlight Companies  |

Breathtec BioMedical Inc. (BTH: CNX) has provided an update on recent corporate events and its immediate outlook and future plans.

The Company is pleased to announce the formation of a new strategic alliance and research agreement with ZeptoMetrix Corp., an industry leader and innovator for Infectious Disease Diagnostics and Development. Plans include an exploratory study to identify biomarkers associated with the Zika virus. The Company views the development of portable devices designed to screen individuals who may carry infections such as Zika at international points of entry as a significant opportunity for its technology. This is a new and exciting area of interest for the Company as current tests for infectious diseases are expensive and often require time consuming lab testing delays.

"Our extensive experience and expertise in propagation and purification of infectious disease cultures will be a tremendous asset in this relationship," states Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix Corporation. "I am excited and pleased in what both ZeptoMetrix(TM) and Breathtec are committed to bringing to this alliance in order to help provide patients with proper results."

Concurrently, Breathtec continues to progress its flagship FAIMS technology with advanced performance testing of its V2 prototype nearing completion. Updates to the system have increased sensitivity and resolution of the device and refinements to circuit design, ionization source and square wave generation. These improvements are subjects of new and important intellectual property scheduled for patent applications as added value opportunities for the Company. Additional efforts include design and fabrication of a clinically optimal breath intake system anticipated to undergo testing in June. As advancements are made, the Company continues to expand investigations into new avenues for future widespread commercial adoption.

In related news, Breathtec welcomes the appointment of Mr. Alfred Wong as Vice President, Corporate Development and Communications. Mr. Wong is an experienced business development professional in the capital markets, technology, logistics, and waste management sectors. He has extensively consulted with early stage startup companies on the development of business plans, management recruitment, transaction negotiation, mergers & acquisitions, and related business development matters.

Breathtec also announced today that Mr. Kal Malhi has resigned his positions as President and Director of the Company to pursue other interests. Breathtec thanks Mr. Malhi for his services and wishes him well on his future endeavors, and further advises that its CEO, Mr. Guy LaTorre now also serves in the role of President. In a related announcement pursuant to the Company's stock option plan, 700,000 incentive stock options exercisable at $0.15 per share for a period of five years have been granted to directors, officers and consultants of the Company.

Moving ahead, and pursuant to its strategic goals and ongoing commitment to shareholder value, Company management has determined to solely dedicate its resources and efforts towards the advancement of its High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS) technology. As a result, the Company and licensor advise their intent to mutually terminate the proposed licensing agreement for the NaNose electronic nose technology. The Company feels the advancement of the FAIMS technology platform and its associated exclusive licensing agreement and broad applicability for medical diagnostics worldwide, offers far greater incentives for commercialization of this singularly promising technology platform. As a result, plans for a clinical study of NaNose previously announced for Surrey, Canada will cease, and resources will be redirected to begin a clinical evaluation process of the FAIMS technology, which is currently scheduled to commence later this year.

About Breathtec Biomedical Inc.

Breathtec Biomedical, Inc. ("Breathtec") was formed to propel innovative research in the area of airborne analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of certain pathogens. Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry. For more information:

In the interest of full disclosure, we call the reader's attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
BTH:CNX AGN:CNX Breathtec BioMedical Inc n/a n/a n/a n/a



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Kitty Parry CEO DeepView

Matt Bird sits down with Kitty Parry, CEO DeepView, at the World Economic Forum at Davos 2019

Emerging Growth

Global Cannabis

Global Cannabis Applications Corp is engaged in the design, acquire data and develop applications for smartphones and tablets. The company offer Citizen Green platform, an end to end infrastructure to…